Information Provided By: 
Fly News Breaks for September 22, 2015
MACK
Sep 22, 2015 | 07:53 EDT
Noting that the PDUFA date for Merrimack's MM-298 drug is October 24, Oppenheimer expects the drug to be approved as a pancreatic cancer treatment. The firm says that the European Society for Medical Oncology recently endorsed the drug as "the best option" for second-line patients. The firm thinks the endorsement is "highly positive" and bodes well for the drug's chances of being approved i n the U.S. The firm reiterates an Outperform rating on the shares.
News For MACK From the Last 2 Days
There are no results for your query MACK
